Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Area of Science:

• Hematology
• Oncology

Background:

• Marginal zone lymphomas (MZLs) represent a rare, indolent category of non-Hodgkin lymphomas.
• MZLs exhibit diverse diagnostic, genetic, and clinical characteristics, impacting treatment strategies.
• The main subtypes include extranodal MZL of mucosa-associated lymphoid tissue, splenic MZL, and nodal MZL.

Purpose of the Study:

• To provide evidence-based recommendations for the diagnosis and management of MZLs.
• To address the diagnostic and therapeutic challenges posed by the heterogeneous presentation and relapsing nature of MZLs.
• To offer guidance specific to the clinical setting in Australia and New Zealand.

Main Methods:

• A review of current evidence and literature.
• Development of consensus-based recommendations.
• Focus on clinical practice guidelines for Australia and New Zealand.

Main Results:

• MZLs are generally associated with good patient outcomes and long survival rates.
• Patients often experience a relapsing-remitting disease course necessitating multiple treatment lines.
• Diagnostic and therapeutic management presents significant challenges for clinicians.

Conclusions:

• Clinicians face challenges in managing the heterogeneity and relapsing course of MZLs.
• Evidence-based recommendations are crucial for optimizing patient care in Australia and New Zealand.
• This position statement aims to guide the effective management of MZLs in the region.